Literature DB >> 26216823

Late Relapse of Testicular Germ Cell Tumors.

Matthew J O'Shaughnessy1, Darren R Feldman2, Brett S Carver1, Joel Sheinfeld3.   

Abstract

Germ cell tumors of the testis have an overall survival rate greater than 90% as a result of a successful multidisciplinary approach to management. Late relapse affects a subset of patients however, and tends to be chemorefractory and the overall prognosis is poor. Surgery is the mainstay in management of late relapse but salvage chemotherapy can be successful. In this review, the clinical presentation and detection of late relapse, clinical outcomes, and predictors of survival in late relapse and the importance of a multidisciplinary treatment approach for successful management of late relapse are discussed.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Germ cell tumor; Late relapse; Retroperitoneal lymph node dissection

Mesh:

Year:  2015        PMID: 26216823     DOI: 10.1016/j.ucl.2015.04.010

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  8 in total

1.  28-year late spermatic cord relapse of a testicular non-seminomatous germ cell tumour, managed robotically.

Authors:  James R Hayes; Michael A S Jewett; Robert J Hamilton
Journal:  Can Urol Assoc J       Date:  2016-07-12       Impact factor: 1.862

Review 2.  Clinically Meaningful Use of Blood Tumor Markers in Oncology.

Authors:  Stefan Holdenrieder; Lance Pagliaro; David Morgenstern; Farshid Dayyani
Journal:  Biomed Res Int       Date:  2016-11-30       Impact factor: 3.411

3.  Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors.

Authors:  Ratnakar Singh; Zeeshan Fazal; Andrea K Corbet; Emmanuel Bikorimana; Jennifer C Rodriguez; Ema M Khan; Khadeeja Shahid; Sarah J Freemantle; Michael J Spinella
Journal:  Cancers (Basel)       Date:  2019-06-08       Impact factor: 6.639

4.  Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers.

Authors:  João Lobo; Ângelo Rodrigues; Rita Guimarães; Mariana Cantante; Paula Lopes; Joaquina Maurício; Jorge Oliveira; Carmen Jerónimo; Rui Henrique
Journal:  Cancers (Basel)       Date:  2019-10-11       Impact factor: 6.639

5.  A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer.

Authors:  Costantine Albany; Zeeshan Fazal; Ratnakar Singh; Emmanuel Bikorimana; Nabil Adra; Nasser H Hanna; Lawrence H Einhorn; Susan M Perkins; George E Sandusky; Brock C Christensen; Harold Keer; Fang Fang; Kenneth P Nephew; Michael J Spinella
Journal:  Cancer Med       Date:  2020-11-01       Impact factor: 4.452

Review 6.  Oncological Follow-up Strategies for Testicular Germ Cell Tumours: A Narrative Review.

Authors:  Ernest Kaufmann; Luca Antonelli; Peter Albers; Clint Cary; Silke Gillessen Sommer; Axel Heidenreich; Christoph Oing; Jan Oldenburg; Phillip Martin Pierorazio; Andrew J Stephenson; Christian Daniel Fankhauser
Journal:  Eur Urol Open Sci       Date:  2022-09-07

7.  Hypermethylation and global remodelling of DNA methylation is associated with acquired cisplatin resistance in testicular germ cell tumours.

Authors:  Zeeshan Fazal; Ratnakar Singh; Fang Fang; Emmanuel Bikorimana; Hannah Baldwin; Andrea Corbet; Megan Tomlin; Cliff Yerby; Nabil Adra; Costantine Albany; Sarah Lee; Sarah J Freemantle; Kenneth P Nephew; Brock C Christensen; Michael J Spinella
Journal:  Epigenetics       Date:  2020-10-30       Impact factor: 4.528

Review 8.  Treatment of germ cell testicular cancer.

Authors:  Ana Koši Kunac; Milena Gnjidić; Zrna Antunac Golubić; Marija Gamulin
Journal:  Acta Clin Croat       Date:  2020-09       Impact factor: 0.780

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.